Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03911700 · ClinicalTrials.gov registry record · NA

Prophylactic Reinforcement of Ventral Abdominal Incisions Trial

A NA study of Open Midline Laparotomy, sponsored by C. R. Bard.

Recruiting
Registry status
NA
Development phase
477
Enrollment target
20
Study locations

NCT03911700 is a NA study of Open Midline Laparotomy that is actively recruiting participants, run by C. R. Bard. The registered enrollment target is 477 participants. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03911700, a NA study of Open Midline Laparotomy, is actively recruiting participants, sponsored by C. R. Bard.

RECRUITING
Registry status
NA
Development phase
477 participants
Enrollment target
20
Study locations

Study Summary

This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.

Conditions Studied

Interventions

  • DEVICE Phasix™ Mesh

Study Locations (20)

Missouri

  • St. Luke's Hospital - Kansas City
  • Cox Health - Springfield
  • Washington University - St Louis

California

  • Keck Medical Center of USC - Los Angeles
  • University of California San Francisco - San Francisco

Connecticut

  • Hartford Hospital - Hartford
  • St. Francis Hospital and Medical Center - Hartford

Minnesota

  • Minneapolis VA Health Care System - Minneapolis
  • University of Minnesota - Minneapolis

Nebraska

  • Nebraska Medical Center - Omaha
  • Nebraska Methodist Hospital - Omaha

Arizona

  • Dignity Health - Phoenix

Georgia

  • Emory University - Atlanta

Illinois

  • OSF Saint Francis Medical Center - Peoria

Trial Details

FieldValue
Enrollment Target 477 participants
Start Date 2019-12-12
Est. Completion 2031-12
Phase NA

Sponsor

C. R. Bard

75 total trials

What the Registry Record Tells You About NCT03911700

The ClinicalTrials.gov registry entry for NCT03911700 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 477 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Open Midline Laparotomy appearing as the primary indexed condition, and to 1 intervention - of which Phasix™ Mesh is the first listed.

NCT03911700 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Missouri, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT03911700 about?

NCT03911700 is a clinical study titled "Prophylactic Reinforcement of Ventral Abdominal Incisions Trial". This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.

What is the current status of trial NCT03911700?

This trial is currently recruiting. It is a NA study. The enrollment target is 477 participants. The study started on 2019-12-12. Estimated completion is 2031-12.

What conditions does trial NCT03911700 study?

This clinical trial studies the following conditions: Open Midline Laparotomy.

What interventions are being tested in trial NCT03911700?

The interventions under investigation include: Phasix™ Mesh (DEVICE).

Who is sponsoring clinical trial NCT03911700?

This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03911700 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.